

Accepted Manuscript

Certolizumab Pegol for the Treatment of Chronic Plaque Psoriasis: Results through 48 Weeks from Two Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Studies (CIMPASI-1 and CIMPASI-2)

Alice B. Gottlieb, MD, PhD, Andrew Blauvelt, MD, MBA, Diamant Thaçi, MD, Craig L. Leonardi, MD, Yves Poulin, MD, Janice Drew, MPH, Luke Peterson, MS, Catherine Arendt, MD, PharmD, Daniel Burge, MD, Kristian Reich, MD

PII: S0190-9622(18)30525-5

DOI: [10.1016/j.jaad.2018.04.012](https://doi.org/10.1016/j.jaad.2018.04.012)

Reference: YMJD 12460

To appear in: *Journal of the American Academy of Dermatology*

Received Date: 6 December 2017

Revised Date: 29 March 2018

Accepted Date: 5 April 2018



Please cite this article as: Gottlieb AB, Blauvelt A, Thaçi D, Leonardi CL, Poulin Y, Drew J, Peterson L, Arendt C, Burge D, Reich K, Certolizumab Pegol for the Treatment of Chronic Plaque Psoriasis: Results through 48 Weeks from Two Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Studies (CIMPASI-1 and CIMPASI-2), *Journal of the American Academy of Dermatology* (2018), doi: 10.1016/j.jaad.2018.04.012.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Certolizumab Pegol for the Treatment of Chronic Plaque Psoriasis: Results through 48 Weeks from Two Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Studies (CIMPASI-1 and CIMPASI-2)

Alice B. Gottlieb, MD, PhD¹ Andrew Blauvelt, MD, MBA² Diamant Thaçi, MD³ Craig L. Leonardi, MD⁴ Yves Poulin, MD⁵ Janice Drew, MPH⁶ Luke Peterson, MS⁷ Catherine Arendt, MD, PharmD⁸ Daniel Burge, MD⁶ Kristian Reich, MD⁹

¹New York Medical College at Metropolitan Hospital, NY, NY; ²Oregon Medical Research Center, Portland, OR; ³Comprehensive Centre Inflammation Medicine, University Hospital of Schleswig-Holstein Campus Lübeck, Lübeck, Germany; ⁴Central Dermatology and Saint Louis University School of Medicine, St. Louis, MO; ⁵Centre de Recherche Dermatologique du Québec Métropolitain, Québec, Canada; ⁶Dermira, Inc., Menlo Park, CA; ⁷UCB Pharma, Raleigh, NC; ⁸UCB Pharma, Brussels, Belgium; ⁹Dermatologikum Hamburg and SCIderm Research Institute, Hamburg, Germany

Corresponding Author: Alice B. Gottlieb, MD, PhD
Professor of Dermatology, Dept of Dermatology
New York Medical College at Metropolitan Hospital
New York, NY 10029
Email: gottlieba@nychhc.org
Phone: 212-423-7467
Fax: 212-423-8464

Funding Sources:

These studies are sponsored and funded by Dermira, Inc. in collaboration with UCB, Inc.

CIMPASI-1 (NCT02326298) and CIMPASI-2 (NCT02326272) were approved by local institutional review boards or independent ethics committees on November 11, 2014 (Quorum IRB Numbers: 29985 and 29986; EudraCT Numbers: 2014-003513-28 and 2014-003486-14)

Acknowledgements:

Medical writing support for this manuscript was provided by Andrew W. Hill, MPH of Prescott Medical Communications Group (Chicago, IL). All costs associated with the development of this manuscript were funded by Dermira, Inc. and UCB, Inc.

Reprint Requests: Alice B. Gottlieb

Conflicts of Interest:

ABG: Consulting and/or other fees: Janssen Inc.; Celgene Corp.; Bristol Myers Squibb Co.; Beiersdorf, Inc.; Abbvie; UCB; Novartis; Incyte; Lilly; Reddy Labs; Valeant; Dermira; Allergan; Sun Pharmaceutical Industries. Research/Educational Grants (paid to Tufts Medical Center): Janssen Incyte; Lilly; Novartis; Allergan; LEO Pharma. **AB:** Consulting honoraria, clinical investigator, and/or speaker's fees: AbbVie; Aclaris; Allergan; Almirall; Amgen; Boehringer Ingelheim; Celgene; Dermavant; Dermira, Inc.; Eli Lilly; Genentech/Roche; GlaxoSmithKline; Janssen; LEO Pharma; Merck Sharp & Dohme; Novartis; Pfizer; Purdue Pharma; Regeneron; Sandoz; Sanofi Genzyme; Sienna Pharmaceuticals; Sun Pharma; UCB Pharma; Valeant; Vidac. **CLL:** Consulting and/or speaker's fees, and/or honoraria, and/or advisory board: AbbVie; Actavis; Amgen; Boehringer Ingelheim Pharma; Celgene; Coherus; Corrona; Dermira, Inc.; Eli Lilly; Galderma; Glenmark; Janssen; LEO Pharma; Merck; Novartis; Pfizer;

Download English Version:

<https://daneshyari.com/en/article/8714897>

Download Persian Version:

<https://daneshyari.com/article/8714897>

[Daneshyari.com](https://daneshyari.com)